Free Trial
→ The Executive Order That Quietly Changed What Your Dollar Means (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:MOLN

Molecular Partners Q3 2026 Earnings Date & Estimates

Molecular Partners logo
$3.85 +0.04 (+1.05%)
Closing price 10/9/2026 03:56 PM Eastern
Extended Trading
$3.84 0.00 (-0.13%)
As of 10/9/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Molecular Partners is scheduled to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. The conference call is scheduled for 4:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
4:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Molecular Partners in Q3 2026

Molecular Partners is expected to post earnings of -$0.46 per share. In the same quarter a year earlier Molecular Partners reported -$0.41 per share. Molecular Partners last reported on August 25, 2026, posting -$0.44 per share and beating the -$0.45 consensus estimate. Molecular Partners has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.46
Prior-Year EPS
-$0.41

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.44 (Beat by +$0.01)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Molecular Partners Q3 2026 Earnings FAQ

Molecular Partners (NASDAQ:MOLN) is scheduled to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens.

Molecular Partners' Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 4:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Molecular Partners to post earnings of -$0.46 per share for Q3 2026.

Molecular Partners Earnings Headlines

Contrasting Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095574
Head to Head Review: AquaBounty Technologies (NASDAQ:AQB) and Molecular Partners (NASDAQ:MOLN)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085530
The Executive Order That Quietly Changed What Your Dollar Means
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
October 11 at 1:00 AM  |  Reagan Gold Group (Ad)
Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base
August 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4087356/molecular-partners-advances-dll3-radio-darpin-mp0712-and-expands-alpha-therapy-pipeline-on-solid-h1-2026-cash-base/
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350195/0/en/molecular-partners-reports-h1-2026-financial-results-and-corporate-highlights-dll3-radiotherapy-mp0712-successfully-advancing-to-higher-dose-level-in-phase-1-2a-study.html
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327452/0/en/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference.html
See More Molecular Partners Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email.

About Molecular Partners

Molecular Partners (NASDAQ:MOLN) AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland, and listed on Nasdaq under the symbol MOLN. The company develops targeted therapies using its proprietary DARPin platform, which is designed to create small, modular proteins that can bind selectively to disease-related targets and be engineered into multi-specific medicines.

Molecular Partners’ research and development activities have focused primarily on oncology and immuno-oncology, including treatments intended to engage or modulate the immune system and address complex biological targets. The company has also developed antiviral candidates, including ensovibep, a DARPin-based therapy investigated for the treatment of COVID-19. Its pipeline has included internally developed programs as well as candidates advanced through collaborations with pharmaceutical and biotechnology companies.

Founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich), Molecular Partners serves global pharmaceutical and biotechnology markets through research, clinical development and strategic partnerships. The company’s programs remain subject to clinical testing and regulatory review, and its focus may evolve as development priorities change.

View Molecular Partners Profile
Earnings Tools